NC-SYNECHRON
Synechron, one of the fastest growing digital, business consulting and technology service providers, announced its corporate brand integration with Double Effect and Team Trade - companies it had acquired in the past few years, to further augment its consulting and technology capabilities. Post-acquisition, Double Effect and Team Trade were operating as independent entities and brands. However, this brand integration strategy will see both these entities merging into the parent company – Synechron, fortifying the overall consulting and technology business/practice. As part of Synechron’s recently announced ‘Power of 3’ strategy, this move is also aimed at providing all consulting and technology services combined with digital under a single brand umbrella in order to leverage Synechron’s robust brand equity, also fueling its ambition of being a billion dollar company by 2020.
Founded in 2003 in Amsterdam, Double Effect houses 100+ business consultants spread across eight global locations. The Dutch consulting firm works for banking and financial institutions including corporate, investment and retail banks, asset management companies and pension as well as insurance services. In 2013, Double Effect became part of the Synechron group.
Team Trade, founded in 2000, is a Paris-based firm specializing in business consulting and financial software integration. The firm has significant presence in Paris, Luxembourg, Milan, London, New York and Singapore covering the European, North American and Asian markets. Team Trade became part of the Synechron group in December 2014.
“Double Effect’s business consulting portfolio is perfectly aligned with the geographical, business, client and service coverage of Synechron. By operating as a consulting arm of the Synechron brand, all our client relationships and alliances will witness a greater value addition through our combined capabilities. We are very excited about this transformation,” said Bas Heijnen, Managing Director, Double Effec t on this occasion.
“Considering the roll out of the recent business transformation strategy by Synechron, this is the right time for brand integration of Team Trade with Synechron as providing technology and consulting services under the merged identity will have a positive impact in the eyes of clients and other stakeholders,” said Pascal Rellier, Managing Director, Team Trade .
“For Synechron, Double Effect and Team Trade, this mutually beneficial move is a major opportunity for offering a niche, augmented set of technology as well as consulting services for the financial services industry. This brand integration will add more depth to Synechron’s current value proposition and enable our global clients to avail business solutions with a 360-degree perspective, encompassing business consulting and technology combined with digital transformation services under a single roof,” commented Faisal Husain, Co-founder and Chief Executive Officer, Synechron .
This brand integration will come into effect on April 4, 2016 and will be a critical step for Synechron in order to strategically re-align its technology and consulting service capabilities in all its service lines.
About Synechron
Synechron, one of the fastest-growing digital, business consulting & technology services providers, is a $350 million firm based in New York. Since inception in 2001, Synechron has been on a steep growth trajectory. With 5,000+ professionals operating in 16 countries across the world, it has presence across USA, Canada, UK, France, The Netherlands, Switzerland, Luxembourg, Serbia, Germany, Italy, UAE, Singapore, Hong Kong, Japan, Australia and Development Centers in India. Visit us at www.synechron.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160331005965/en/
Contact:
Synechron
Atul Tajave
Manager - Global Marketing &
Communication
synechron-mediarelations@synechron.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
